|
NAA30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.69539945918496E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.25359747424636E-11 |
| Normal-vs-Stage2 |
3.430600E-04 |
| Normal-vs-Stage3 |
8.69429972460978E-10 |
| Normal-vs-Stage4 |
9.65709734401798E-11 |
| Stage1-vs-Stage2 |
1.476160E-01 |
| Stage1-vs-Stage3 |
4.099600E-01 |
| Stage1-vs-Stage4 |
9.460400E-03 |
| Stage2-vs-Stage3 |
6.598200E-02 |
| Stage2-vs-Stage4 |
2.602200E-03 |
| Stage3-vs-Stage4 |
1.340630E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.14508402759839E-12 |
| Normal-vs-AfricanAmerican |
1.424910E-03 |
| Normal-vs-Asian |
3.13539999519108E-08 |
| Caucasian-vs-AfricanAmerican |
3.810800E-01 |
| Caucasian-vs-Asian |
6.521600E-01 |
| AfricanAmerican-vs-Asian |
2.740600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.76169984050989E-10 |
| Normal-vs-Female |
1.32840405342449E-11 |
| Male-vs-Female |
6.301000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.90050033675038E-10 |
| Normal-vs-Age(41-60Yrs) |
2.63009947154558E-10 |
| Normal-vs-Age(61-80Yrs) |
6.48359999022574E-09 |
| Normal-vs-Age(81-100Yrs) |
5.175100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.813000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.730000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.456200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.557400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.476400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.179000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.510180E-01 |
| Classical-VS-Follicular |
9.313200E-01 |
| Classical-VS-Other |
5.131000E-01 |
| Classical-VS-Normal |
1.13569999959928E-07 |
| Tall-VS-Follicular |
2.565800E-01 |
| Tall-VS-Other |
9.397000E-01 |
| Tall-VS-Normal |
1.18049999997538E-07 |
| Follicular-VS-Other |
5.966000E-01 |
| Follicular-VS-Normal |
5.27640000025364E-07 |
| Other-VS-Normal |
8.721000E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.99230015502417E-10 |
| Normal-vs-N1 |
1.89150028973017E-10 |
| N0-vs-N1 |
1.267730E-02 |
|
|
